1. Current Status, Position
Prof. Dr. Declerck (PharmD, PhD) is Professor in Pharmaceutical Biotechnology and Dean at the Faculty of Pharmaceutical Sciences at the University of Leuven, Belgium.
Professor Paul J. Declerck, PharmD, PhD, obtained his Ph.D. in Pharmaceutical Sciences from the KU Leuven (Belgium) in 1984. After a post-doctoral training in the Laboratory of Biochemical Cytology (Prof. Dr. C. de Duve) at the Rockefeller University in New York, he joined in 1986 the Center for Molecular and Vascular Biology (Prof. D. Collen) at the KU Leuven. In 1991, he was appointed professor of Pharmaceutical Biotechnology at the Faculty of Pharmaceutical Sciences. He became full professor in 1997. He is Research Director of the Laboratory for Therapeutic and Diagnostic Antibodies at the Department of Pharmaceutical and Pharmacological Sciences (KU Leuven).
3. Research Area
His research is focused on structure-function relationships of (recombinant) proteins and on the development of monoclonal antibodies for research, diagnostic and therapeutic purposes. He has expertise in the area of recombinant proteins, monoclonal antibody technology, biotechnology, drug development, structure-function relationship in proteins, biosimilars.
4. Conflict of interest: Prof. Dr. Declerck has received speakers' fee and/or honoraria for lectures or (non-product specific) advisory board meetings from Abbvie, Amgen, Celltrion, Hospira, Merck-Serono, Novo Nordisk, Pfizer, Roche.